logo
#

Latest news with #MichaelReardon

Anniversary of climber famed for his adrenaline and glamour but whose remains were never found
Anniversary of climber famed for his adrenaline and glamour but whose remains were never found

Irish Examiner

timea day ago

  • Irish Examiner

Anniversary of climber famed for his adrenaline and glamour but whose remains were never found

The eternal human quest for adrenaline-fueled adventure took on a new aspect in the 1970s. This involved finding a sheer cliff, maybe 50 metres high, and climbing to the top without the aid of ropes or safety equipment. Fall early on and you had a sporting chance of spending the remainder of your life in a wheelchair; come off anywhere near the top and you were headed for 'the pearly gates'. The reasons not to take part in such an activity seem irrefutable, yet the sport of free solo climbing was soon attracting growing numbers of participants. Michael Reardon climbs on the Gap of Dunloe, County Kerry. Picture: Damon Corso One reason why some were prepared to ignore the possible gravitational consequences from such activities may be a reaction to living in an increasingly anodyne world where every effort is made to engineer risk from our lives. Children no longer walk to school, are often discouraged from running in playgrounds, while some schools require them to wear goggles when playing conkers. Adults can't buy more than two packets of paracetamol, are advised to only to go outside in the morning and evening on hot, summer days, while some universities ban students from throwing mortarboards at graduation. If Christopher Columbus lived today, he could hardly have discovered America. An apparatchik would surely have appeared on the quayside before he sailed and listed several reasons why the Santa Maria could not be licensed for transatlantic travel. Health and safety inspections may have made our lives safer and more comfortable, but they have also assuredly made them less challenging and more boring. Invariably, however, some free-spirited people will resolutely refuse to accept the constraints that safety experts impose on the rest of us. Free soloist Michael Reardon climbing in his beloved Gap of Dunloe, Killarney. Picture: Valerie O'Sullivan Rockclimber Michael Reardon was one such person. American-born, but of Irish ancestry, he lived from an early age the expansive life common among those who eventually broaden the boundaries of human achievement. In the 1980s he was a member of a heavy metal band and later worked as a writer and film producer. He was best known, however, for belonging to an elite group of top-level climbers — known as the Outlaws — whose members insisted on making ascents of cliff faces while unfettered by ropes. For some people, this is climbing in its purest and most stylish form — to the rest of us, it appears foolhardy in the extreme. But then we should remember the age-old truism that those who dare to push back the frontiers of the possible are invariably considered foolhardy by their contemporaries. Public opprobrium was heaped on the 'reckless' first climbers to reach the summit of the Matterhorn. It also fell upon those who battled with the north face of the Eiger Mountain in the 1930s. And in more recent years, it has fallen upon women — but not so much on men — who have continued with cutting-edge climbing after having children. Nevertheless, without people prepared to take risks and push themselves beyond their comfort zone, the world's greatest mountains would remain unclimbed, European explorers could hardly have reached America and the lunar dust would remain footprint-free. A restless search for advancement is a key element of the human condition. If it exists, then sooner or later somebody, possessing raw courage beyond what the vast majority of us can comprehend, will want to reach it, climb it, traverse it, or explore it. Reardon was such a person, and inevitably on his Irish visits, he hit the local climbing scene like a tornado. Spurning long-held conventions on safety, he soloed 240 of our hardest climbs. Locals observed in awe as, with his trademark blonde locks flowing in the breeze, he glided unprotected up cliffs that heretofore had only been attempted by Ireland's best climbers using ropes and modern equipment. Irish Examiner, Saturday, July 14, 2007: Search for missing climber Michael Reardon In the end, it was not a fall but the ocean that claimed him. This July marks 18 years since he was swept out to sea while climbing in Kerry. Unsurprisingly, perhaps, many concluded that the world's best-known solo climber had finally overreached himself and that his loss was the result of a climbing error and an ocean fall. Reality was more mundane, but no less tragic. A rogue wave knocked Reardon from a rock during a photo shoot following another successful ascent, and his remains were never recovered. When I spoke to his friend, Kerry mountain climber, Con Moriarty, he quickly pointed out that Reardon was — despite his awesome reputation — no daredevil': He was an extremely cautious and calculating climber, and I never saw him take an unnecessary or foolhardy risk.' Irish Examiner. Wednesday, October 3 2007 Inquest rules that climber Michael Reardon died by misadventure Reardon is now remembered for the fact that in a tragically short career, he put adrenaline and glamour into rockclimbing that would later be harnessed by world-renowned climbers such as Alex Honnold. Locals and climbers, family and friends of climber free soloist Michael Reardon US waving at the memorial service on Valentia Island for climber Michael Reardon in 2007. Picture: Don MacMonagle With his simple, flowing technique, he brought challenges that would have previously been considered outlandish firmly within the realm of possibility for future generations of climbers. Michael Reardon: May 1, 1965 – July 13, 2007. Picture: Valerie O'Sullivan

Anteris Technologies Reaches Clinical Milestone: 100 patients treated with DurAVR® THV
Anteris Technologies Reaches Clinical Milestone: 100 patients treated with DurAVR® THV

Yahoo

time31-03-2025

  • Business
  • Yahoo

Anteris Technologies Reaches Clinical Milestone: 100 patients treated with DurAVR® THV

MINNEAPOLIS and BRISBANE, Australia, March 31, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris® or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices, announces a significant milestone in our mission to restore heart valve patients to healthy function. Our first in class, biomimetic DurAVR® Transcatheter Heart Valve (THV) has now been used to treat over 100 patients worldwide, marking a major achievement in our goal to revolutionize cardiac care in patients affected by severe aortic stenosis. Highlights: Over 100 patients successfully treated with the DurAVR® THV, including de novo (first time) aortic stenosis cases, valve-in-valve (ViV) patients and complex anatomies such as bicuspid aortic valve patients* 65 patients have successfully completed the primary endpoint measures of safety and efficacy, including hemodynamic benefit at 30-days post implant One-year efficacy data on 37 aortic stenosis patients continues to validate the exceptional hemodynamic performance, with sustained large effective orifice areas (EOAs) and low mean pressure gradients (MPGs) Excellent safety profile demonstrated at one-year, with no valve or cardiovascular related mortality Range of valve sizes used to accommodate a broad patient population Anteris Chief Medical Officer, Chris Meduri, M.D., commented: 'We are incredibly proud to have reached this milestone, which represents years of dedication, research, and importantly collaboration with expert physicians in the field. The excellent hemodynamic performance we are seeing is noteworthy in that it shows that DurAVR® has the potential to restore natural heart valve function and thereby redefine what success looks like in the treatment of aortic stenosis.' Dr. Michael Reardon, Allison Family Distinguished Chair of Cardiovascular Research and Professor of Cardiothoracic Surgery at the Houston Methodist Hospital and Study Chair of the DurAVR® THV Pivotal Trial said, 'We are building on a strong foundation of clinical evidence, and we remain committed to rigorous scientific evaluation as we progress toward the all-risk, head-to-head, DurAVR® registration trial.' Vice Chairman and CEO, Wayne Paterson added, 'This is a clinical milestone for the company and its investors. Not only have we crossed the threshold of having treated over 100 patients, but we have achieved results that are clinically relevant and significantly differentiated to current therapies. DurAVR® is the first new class of product in this space in many years and the current results across often complex patients confirms the value of the product for physicians and patients as we move into our registration trial this year.' The Company remains on track to commence the DurAVR® THV Pivotal Trial in the third quarter of 2025, pending U.S. Food and Drug Administration ("FDA") approval. *A bicuspid aortic valve (BAV) is a congenital heart condition where the aortic valve, which regulates blood flow from the heart to the aorta, has only two leaflets (or flaps) instead of the normal three. About Anteris Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients. Anteris' lead product, the DurAVR® Transcatheter Heart Valve (THV), was designed in partnership with the world's leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR® THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR® THV is made using a single piece of molded ADAPT® tissue, Anteris' patented anti-calcification tissue technology. ADAPT® tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR® THV System is comprised of the DurAVR® valve, the ADAPT® tissue, and the balloon-expandable ComASUR® Delivery System. Forward-Looking Statements This announcement contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. Forward-looking statements generally are identified by the words 'believe,' 'project,' 'expect,' 'anticipate,' 'estimate,' 'intend,' 'budget,' 'target,' 'aim,' 'strategy,' 'plan,' 'guidance,' 'outlook,' 'intend,' 'may,' 'should,' 'could,' 'will,' 'would,' 'will be,' 'will continue,' 'will likely result' and similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described under 'Risk Factors' in Anteris' Annual Report on Form 10-K for the fiscal period ended December 31, 2024 that was filed with the SEC and ASX. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, neither ATL or Anteris assume any obligation to update any of these forward-looking statements to conform these statements to actual results or revised expectations. Authorisation and Additional information This announcement was authorised for release on the ASX by the Board of Directors. For more information: Investor Relationsinvestor@ OrmsbyAnteris Technologies Global Corp.+61 1300 550 310 | +61 7 3152 3200 Investor Relations (US)mchatterjee@ Chatterjee, Life Science Group+1 917 330 4269Website X @AnterisTech LinkedIn in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store